Baseline adjusted robust regression for baseline serum soluble interleukin 2 receptor (sIL2R) predicting change in 28 joint disease activity score (DAS28) after six and 22 weeks
| Explanatory variable | DAS28 change from baseline | |||||||
|---|---|---|---|---|---|---|---|---|
| After 6 weeks | After 22 weeks | |||||||
| Coefficient (95% CI) | p Value | Coefficient (95% CI) | p Value | |||||
| Baseline sIL2R (per 100 U/ml) | 0.2054 (0.0035 to 0.4073) | 0.047 | 0.0152 (−0.1872 to 0.2176) | 0.88 | ||||
| Baseline DAS28 score | 0.0585 (−0.5327 to 0.6498) | 0.84 | −0.3067 (−0.8730 to 0.2595) | 0.27 | ||||
| Infliximab dose (mg/kg) | 0.1313 (−0.3719 to 0.6346) | 0.59 | 0.0185 (−0.4515 to 0.4885) | 0.94 | ||||
| Constant | −4.995 (−8.708 to −1.2823) | −0.1731 (−3.220 to 2.873) | ||||||